Tardive Dyskinesia TD News 
Wednesday, 20 January 2010

Association of the HSPG2 Gene with Neuroleptic-Induced Tardive Dyskinesia.

Syu A, Ishiguro H, Inada T, Horiuchi Y, Tanaka S, Ishikawa M, Arai M, Itokawa M, Niizato K, Iritani S, Ozaki N, Takahashi M, Kakita A, Takahashi H, Nawa H, Keino-Masu K, Arikawa-Hirasawa E, Arinami T.

[1] Department of Medical Genetics and Department of Molecular Neurobiology, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Ibaraki, Japan [2] CREST, Japan Science and Technology Agency, Kawaguchi-shi, Saitama, Japan.

Tardive dyskinesia (TD) is characterized by repetitive, involuntary, and purposeless movements that develop in patients treated with long-term dopaminergic antagonists, usually antipsychotics. By a genome-wide association screening of TD in 50 Japanese schizophrenia patients with treatment-resistant TD and 50 Japanese schizophrenia patients without TD (non-TD group) and subsequent confirmation in independent samples of 36 treatment-resistant TD and 136 non-TD subjects, we identified association of a single nucleotide polymorphism, rs2445142, (allelic p=2 x 10(-5)) in the HSPG2 (heparan sulfate proteoglycan 2, perlecan) gene with TD. The risk allele was significantly associated with higher expression of HSPG2 in postmortem human prefrontal brain (p<0.01). Administration of daily injection of haloperidol (HDL) for 50 weeks significantly reduced Hspg2 expression in mouse brains (p<0.001). Vacuous chewing movements (VCMs) induced by 7-week injection of haloperidol-reserpine were significantly infrequent in adult Hspg2 hetero-knockout mice compared with wild-type littermates (p<0.001). Treatment by the acetylcholinesterase inhibitor, physostigmine, was significantly effective for reduction of VCMs in wild-type mice but not in Hspg2 hetero-knockout mice. These findings suggest that the HSPG2 gene is involved in neuroleptic-induced TD and higher expression of HSPG2, probably even after antipsychotic treatment, and may be associated with TD susceptibility.Neuropsychopharmacology advance online publication, 13 January 2010; doi:10.1038/npp.2009.220.

PMID: 20072119

POSTED BY: DW AT 09:58 am   |  Permalink   |  E-mail this

Tardive Dyskinesia Web for TD treatment, Tardive Dyskinesia Symptoms, causes and the latest news on Metoclopramide Reglan Lawsuit  Litigation and Settlements and any news of a FDA Reglan Recall Talk to Reglan side effects metoclopramide lawyer about filing a metoclopramide lawsuit, metoclopramide Reglan lawsuit , side effects from metoclopramide reglan drug, metoclopramide reglan class action lawsuit and possible metoclopramide recall news

WILLIS LAW FIRM 1221 McKinney # 3333  Houston, Texas 77010

 Call Toll Free at 1-888-5-TARDIVE

THIS WEBSITE IS ATTORNEY ADVERTISING

_____________________________________________________________________________________________